DrugBiological
Interleukin-11 clinical trials
Includes 11 studies of Oprelvekin.
- studies test it
- 13
- open now
- 1
- in phase 3
- 1
- first study started
- 2000
Keep track of what changes. Save the Interleukin-11 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2018 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 10
- Phase 3
- 1
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 10
Margaret Ragni (2) · University of Pittsburgh (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Shanghai Children's Medical Center (1) · M.D. Anderson Cancer Center (1) · Fred Hutchinson Cancer Center (1) · Fudan University (1) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Filgrastim (3) · Granulocyte Colony-Stimulating Factor (1) · Rituximab (1) · Yttrium Y-90 ibritumomab tiuxetan (1) · Ibritumomab tiuxetan (1)
Studies
Open first, then newest update. How each study uses Interleukin-11 is read from its arms, and is right about nine times in ten.
Testing it · 13
- G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell TransplantationRecruitingPhase 2Fudan UniversityNCT07362810Written as G-CSF+IL-11
- Interleukin-11 Can Prevent and Treat of Radioactive Oral MucitisStatus unknownPhase 3Zhejiang Cancer HospitalNCT03720340Written as Recombinant Human Interleukin-11
- IL-11 in Adults With Von Willebrand Disease Undergoing SurgeryTerminatedPhase 2Margaret RagniNCT00524225Written as Neumega (Oprelvekin, Interleukin 11, IL-11)
- Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT00012298Written as oprelvekin
- IL-11 in Women With Von Willebrand Disease and Refractory MenorrhagiaCompletedPhase 2Margaret RagniNCT00524342Written as Oprelvekin, Interleukin 11, IL-11
- Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced ThrombocytopeniaTerminatedPhase 2PfizerNCT00886743Written as oprelvekin
- Phase II Study of IL-11 (Neumega) in Von Willebrand DiseaseCompletedPhase 2University of PittsburghNCT00151125Written as recombinant interleukin-11
- Efficacy and Safety of IL-11 in DDAVP UnresponsiveCompletedPhase 2University of PittsburghNCT00994929Written as Neumega (Oprelvekin, Interleukin 11, IL-11)
- Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALLCompletedPhase 4Shanghai Children's Medical CenterNCT02314273Written as rhIL-11
- Study Evaluating rhIL-11 in Active Crohn's DiseaseCompletedPhase 2Wyeth is now a wholly owned subsidiary of PfizerNCT00040521Written as Recombinant Human Interleukin-11 (rhIL-11)
- Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) PatientsCompletedPhase 2M.D. Anderson Cancer CenterNCT00493181Written as Interleukin-11 (IL-11 or Neumega)
- Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid TumorsCompletedPhase 2Fred Hutchinson Cancer CenterNCT00004157Written as recombinant interleukin-11
- Study Evaluating rhIL-11 in Left-Sided Ulcerative ColitisTerminatedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00038922Written as rhIL-11
As the comparator · 4 — what is tested is compared with Interleukin-11
- A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11RecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT06759636Written as Recombinant Human Interleukin-11 (rhIL-11)
- A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11CompletedPhase 3Beijing Northland Biotech. Co., Ltd.NCT01663441Written as rhIL-11
- Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With ThrombocytopeniaStatus unknownPhase 2Fudan UniversityNCT03823079Written as rhIL-11
- Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of ThrombocytopeniaStatus unknownPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT02241031Written as thrombopoietin (TPO) and interleukin-11
Codes
What other systems call Interleukin-11 · ClinicalTrials.gg INT008598
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 1311380 | — | One source FDA |
| Wikidata | Q24784118 | Interleukin-11 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.